Aytu BioPharma 관리

관리 기준 확인 2/4

Aytu BioPharma CEO는 Josh Disbrow, Apr2015 에 임명되었습니다 의 임기는 7.25 년입니다. 총 연간 보상은 $ 567.31K, 100% 로 구성됩니다. 100% 급여 및 0% 보너스(회사 주식 및 옵션 포함). 는 € 123.42K 가치에 해당하는 회사 주식의 1.61% 직접 소유합니다. 123.42K. 경영진과 이사회의 평균 재임 기간은 각각 0.4 년과 6.9 년입니다.

주요 정보

Josh Disbrow

최고 경영자

US$567.3k

총 보상

CEO 급여 비율	100.0%
CEO 임기	8yrs
CEO 소유권	1.6%
경영진 평균 재임 기간	less than a year
이사회 평균 재임 기간	6.9yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Josh Disbrow 의 보수는 Aytu BioPharma 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Dec 31 2022	n/a	n/a	-US$78m
Sep 30 2022	n/a	n/a	-US$83m
Jun 30 2022	US$567k	US$567k	-US$110m
Mar 31 2022	n/a	n/a	-US$111m
Dec 31 2021	n/a	n/a	-US$84m
Sep 30 2021	n/a	n/a	-US$82m
Jun 30 2021	US$6m	US$545k	-US$58m
Mar 31 2021	n/a	n/a	-US$42m
Dec 31 2020	n/a	n/a	-US$22m
Sep 30 2020	n/a	n/a	-US$13m
Jun 30 2020	US$2m	US$608k	-US$14m
Mar 31 2020	n/a	n/a	-US$25m
Dec 31 2019	n/a	n/a	-US$24m
Sep 30 2019	n/a	n/a	-US$29m
Jun 30 2019	US$1m	US$330k	-US$27m
Mar 31 2019	n/a	n/a	-US$12m
Dec 31 2018	n/a	n/a	-US$10m
Sep 30 2018	n/a	n/a	-US$9m
Jun 30 2018	US$606k	US$303k	-US$10m
Mar 31 2018	n/a	n/a	-US$17m
Dec 31 2017	n/a	n/a	-US$20m
Sep 30 2017	n/a	n/a	-US$21m
Jun 30 2017	US$1m	US$250k	-US$23m
Mar 31 2017	n/a	n/a	-US$31m
Dec 31 2016	n/a	n/a	-US$33m
Sep 30 2016	n/a	n/a	-US$32m
Jun 30 2016	US$1m	US$250k	-US$28m

보상 대 시장: Josh 의 총 보상 ($USD 567.31K )은 German 시장( $USD 471.14K ).

보상과 수익: Josh 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Josh Disbrow (47 yo)

8yrs

테뉴어

US$567,308

보상

Mr. Joshua R. Disbrow, also known as Josh, is Chairman of the Board at Aytu Biopharma, Inc. (formerly known as Aytu BioScience, Inc.) since July 2016 and serves as its Chief Executive Officer. He serves as...

리더십 팀

이름	위치	테뉴어	보상	소유권
Joshua Disbrow	Chairman & CEO	8yrs	US$567.31k	1.61% € 123.4k
Mark Oki	CFO, Secretary & Treasurer	1.3yrs	US$352.60k	0.27% € 20.4k
Christopher Brooke	Chief Operating Officer	less than a year	데이터 없음	1.63% € 125.1k
Victoria Cordova	Vice President of People & Culture	less than a year	데이터 없음	데이터 없음
Jarrett Disbrow	Chief Business Officer & President of Consumer Health	less than a year	US$793.41k	0.36% € 27.4k
Greg Pyszczymuka	Chief Commercial Officer	no data	데이터 없음	0.25% € 19.5k
Russ McMahen	Senior Vice President of Research & Development	no data	데이터 없음	데이터 없음
Ryan Selhorn	Executive VP of Finance & Business Optimization	less than a year	데이터 없음	데이터 없음

0.4yrs

평균 재임 기간

47yo

평균 연령

경험이 풍부한 관리: AY20 의 관리팀은 경험 (평균 재직 기간 0.4 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Joshua Disbrow	Chairman & CEO	7.3yrs	US$567.31k	1.61% € 123.4k
Vivian Liu	Independent Director	less than a year	데이터 없음	0.19% € 14.6k
John Donofrio	Lead Independent Director	6.8yrs	US$75.00k	0.021% € 1.6k
Carl Dockery	Independent Director	7yrs	US$70.00k	0.21% € 15.9k

6.9yrs

평균 재임 기간

57yo

평균 연령

경험이 풍부한 이사회: AY20 의 이사회는 경험(평균 재직 기간 6.9 년)으로 간주됩니다.

Aytu BioPharma 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Russ McMahen to Leave as Senior Vice President of Research and Development of Aytu BioPharma, Inc

Aytu BioPharma, Inc., Annual General Meeting, Jun 26, 2024

Aytu BioPharma, Inc. Appoints Abhinav "Abi" Jain as Board of Directors

Gary Cantrell to Retire from the Aytu BioPharma, Inc.'s Board of Directors, Effective December 31, 2022

Aytu BioPharma, Inc. Announces the Passing of Michael Macaluso, Board Member

Aytu BioPharma, Inc. Announces Management Changes

Recent updates

Russ McMahen to Leave as Senior Vice President of Research and Development of Aytu BioPharma, Inc

Aytu BioPharma, Inc. to Report Q1, 2025 Results on Nov 13, 2024

Aytu BioPharma, Inc. to Report Q4, 2024 Results on Sep 26, 2024

An unknown buyer acquired Innovus Pharmaceuticals, Inc. from Aytu BioPharma, Inc. (NasdaqCM:AYTU).

Aytu BioPharma, Inc., Annual General Meeting, Jun 26, 2024

Aytu BioPharma, Inc. to Report Q3, 2024 Results on May 15, 2024

Aytu BioPharma, Inc. to Report Q2, 2024 Results on Feb 14, 2024

Aytu BioPharma, Inc. to Report Q1, 2024 Results on Nov 14, 2023

Aytu BioPharma, Inc. Announces Approval of the Cotempla XR-ODT Manufacturing Site Transfer Prior Approval Supplement

Aytu BioPharma, Inc. announced delayed annual 10-K filing

Aytu BioPharma, Inc. to Report Q4, 2023 Results on Sep 27, 2023

Aytu BioPharma, Inc. Announces Submission of Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement

Aytu BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $3.999955 million.

Aytu BioPharma, Inc. Appoints Abhinav "Abi" Jain as Board of Directors

Aytu BioPharma, Inc. announced delayed 10-Q filing

Aytu BioPharma, Inc. to Report Q2, 2023 Results on Feb 14, 2023

Aytu Biopharma Regains Nasdaq Minimum Bid Price Compliance

Aytu Biopharma, Inc. Continues Availability of Adzenys XR-ODT(R) as the Only FDA-Approved Orally Disintegrating Tablet (ODT) Medication That Is Bioequivalent to Adderall XR(R) for Adhd Patients

Gary Cantrell to Retire from the Aytu BioPharma, Inc.'s Board of Directors, Effective December 31, 2022

Aytu BioPharma Receives A 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule

Aytu BioPharma, Inc. Announces the Passing of Michael Macaluso, Board Member

First quarter 2023 earnings released: US$0.057 loss per share (vs US$1.09 loss in 1Q 2022)

Forecast to breakeven in 2025

Aytu BioPharma, Inc. Announces Management Changes

Aytu BioPharma, Inc. to Report Q1, 2023 Results on Nov 14, 2022

Aytu Biopharma Announces Continuing Availability of Adhd Medication Adzenys Xr-Odt(R) in Response to Reported Generic Adderall(R) Xr Supply Disruptions

Full year 2022 earnings released: US$3.75 loss per share (vs US$3.48 loss in FY 2021)

Aytu BioPharma, Inc. to Report Q4, 2022 Results on Sep 27, 2022

Aytu BioPharma, Inc. Announces Addition of Fourth Patent License for Ar101/Enzastaurin

Aytu BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $9.99825 million.

Aytu BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $9.99825 million.

Aytu Biopharma, Inc. Appoints Vivian Liu to Its Board of Directors and as Member of the Nominating & Corporate Governance Committee, Effective July 1, 2022

Aytu BioPharma Receives Letter from the Nasdaq

Third quarter 2022 earnings released: US$1.79 loss per share (vs US$1.41 loss in 3Q 2021)

Insufficient new directors

Aytu BioPharma, Inc., Annual General Meeting, May 18, 2022

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Denovo Biopharma LLC Announces Partner Aytu BioPharma Receives FDA Clearance and Orphan Drug Designation for Enzastaurin in Vascular Ehlers-Danlos Syndrome

First quarter 2022 earnings released: US$1.09 loss per share (vs US$0.35 loss in 1Q 2021)

Full year 2021 earnings released: US$3.48 loss per share (vs US$3.01 loss in FY 2020)

Forecast to breakeven in 2023

Insufficient new directors

Insufficient new directors

Insufficient new directors

Independent Director Steven Boyd has left the company

Aytu Biopharma, Inc.(NasdaqCM:AYTU) dropped from Russell 3000E Value Index

Aytu Biopharma, Inc. Plans to Close Grand Prairie, Texas Manufacturing Operations over the Next Eighteen Months

CFO, Secretary & Treasurer has left the company

Independent Director has left the company

Second quarter 2021 earnings released: US$0.72 loss per share (vs US$0.12 loss in 2Q 2020)

Revenue beats expectations

Aytu BioScience, Inc. (NasdaqCM:AYTU) entered into definitive merger agreement to acquire Neos Therapeutics, Inc. (NasdaqGM:NEOS) for $37.8 million.

Aytu BioScience, Inc. to Report Q1, 2021 Results on Nov 12, 2020

Aytu BioScience, Inc. to Report Q4, 2020 Results on Oct 06, 2020

Aytu BioScience, Inc. announced delayed annual 10-K filing

New 90-day low - €0.86

New 90-day low - €1.10

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령